Comparative Pharmacology
Head-to-head clinical analysis: LEGUBETI versus MEPSEVII.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEGUBETI versus MEPSEVII.
LEGUBETI vs MEPSEVII
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Legubeti is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin secretion.
MEPSEVII (vestronidase alfa) is a recombinant form of human beta-glucuronidase that hydrolyzes accumulated glycosaminoglycans (GAGs) in lysosomes, restoring enzymatic activity in patients with Mucopolysaccharidosis VII (Sly syndrome).
500 mg orally twice daily
1 mg/kg administered intravenously once weekly over 4 hours.
None Documented
None Documented
Terminal half-life: 12 hours; steady-state reached after 2-3 days; adjust dose in renal impairment
Terminal elimination half-life: 9.4 hours (range 6.3–16.6 hours) in patients with mucopolysaccharidosis VII; supports weekly intravenous dosing.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal: negligible; primarily catabolized via peptide hydrolysis to amino acids, which are recycled or excreted in urine as metabolites.
Category C
Category C
Unknown
Unknown